NanoViricides, Inc. has completed manufacturing of its NV-387 Oral Gummies drug product in preparation for patient dosing as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo. The company announced this milestone alongside its participation in NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company's broad-spectrum antiviral platform.
The completion of NV-387 Oral Gummies manufacturing represents a critical step toward addressing viral diseases that continue to pose significant global health threats. NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, establishing a safety profile that enables progression to efficacy testing. The company is currently focused on advancing NV-387 into Phase II human clinical trials, with the Democratic Republic of Congo trial targeting monkeypox specifically.
NV-387's importance stems from its broad-spectrum antiviral properties that could potentially treat multiple respiratory viral infections. According to company information available at https://www.nanoviricides.com, the drug candidate is planned for development as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. The company notes that NV-387 is also effective in animal models for Monkeypox, Smallpox, and Measles, suggesting potential applications beyond respiratory illnesses.
The advancement of NV-387 comes at a time when antiviral treatments remain crucial for managing both endemic and emerging viral threats. The successful Phase I safety study in healthy volunteers provides a foundation for further clinical investigation, particularly for monkeypox, which has seen outbreaks in multiple regions. The company's progress can be tracked through updates available in their newsroom at https://ibn.fm/NNVC.
Beyond NV-387, NanoViricides is developing other antiviral candidates, including NV-HHV-1 for the treatment of all Herpesvirus infections. The company describes itself as creating special purpose nanomaterials for antiviral therapy, representing a novel approach to viral treatment. However, the company cannot project an exact date for filing an Investigational New Drug application for any of its drugs because of dependence on a number of external collaborators and consultants.
The completion of NV-387 Oral Gummies manufacturing and preparation for Phase II trials represents progress in antiviral drug development that could have implications for global health preparedness. As viral diseases continue to emerge and re-emerge, broad-spectrum antivirals like NV-387 could provide important tools for healthcare systems worldwide. The upcoming presentation at NIBA's investment conference will provide further details on the company's platform and development timeline.
